à·ÈºÒÅµÓºÅËéÇÂ¢éÒÇ¡èÓ àÅ¢·Õè 127 ËÁÙè 1 µ.ËéÇÂ¢éÒÇ¡èÓ Í.¨Ø¹ ¨Ç.¾ÐàÂÒ 56150 â·ÃÈÑ¾·ì: 0-5445-9031 â·ÃÊÒÃ: 0-5445-9356

ÂÔ¹´ÕµéÍ¹ÃÑº¤Ø³ ºØ¤¤Å·ÑèÇä»
IP ¢Í§¤Ø³¤×Í 3.236.97.59

Apple ÂÍÁÃÑº¡ÒÃÅçÍ¡´ÒÇ¹ìã¹»ÃÐà·È¨Õ¹ Êè§¼ÅãËé¡ÒÃ¼ÅÔµ iPhone ÅèÒªéÒ¡ÇèÒ¡ÓË¹´(26 ¾.¤. 2565, 09:39)

µÑé§ÈÙ¹Âì»¯ÔºÑµÔ¡ÒÃ ¡ÃÐ·ÃÇ§ÈÖ¡ÉÒ¸Ô¡ÒÃ¢Ñºà¤Å×èÍ¹¹âÂºÒÂàÃè§´èÇ¹(26 ¾.¤. 2565, 09:34)

·Ê.ËÒÃ×Í UNEP ¨Ñ´¡ÒÃÁÅ¾ÔÉ¨Ò¡¾ÅÒÊµÔ¡ ÊÒÃà¤ÁÕ(26 ¾.¤. 2565, 09:30)

¹ÒÂ¡Ï ¶Ö§¡ÃØ§âµà¡ÕÂÇáÅéÇ ÃèÇÁàÇ·Õ Nikkei Forum ¤ÃÑé§·Õè 27 ¡ÅèÒÇ»Ò°¡¶ÒºèÒÂÇÑ¹¹Õé(26 ¾.¤. 2565, 09:24)

»À. á¨é§àµ×Í¹ 5 ¨Ñ§ËÇÑ´ ÃÐÇÑ§¹éÓ·èÇÁ©Ñº¾ÅÑ¹ ªèÇ§ÇÑ¹·Õè 27-29 ¾.¤.¹Õé(26 ¾.¤. 2565, 09:20)

¤ÇÒÁàª×èÍµÔ´ºèÇ§¡ÃÃÁá¿¹äÁè´Õ ·èÍ§¤Ò¶ÒàÅÔ¡á¿¹ ÊÇ´»Øêºä»á¹èµÅÍ´¡ÒÅ (26 ¾.¤. 2565, 09:15)

âË§ÇàÎé§¨ÁÙ¡¹ÒÂáºº ¢éÍá¹Ð¹Ó¡èÍ¹ÈÑÅÂ¡ÃÃÁÊÓËÃÑºË¹ØèÁæ àÊÃÔÁ¤ÇÒÁÁÑè¹ã¨ 100%(26 ¾.¤. 2565, 09:09)

ÍèÇÁ ¤ÙàÇµàµ×Í¹ÀÑÂà¨Í¾ÒÂØ·ÃÒÂ¶ÅèÁ«éÓÍÕ¡ÃÐÅÍ¡(26 ¾.¤. 2565, 09:02)

áºÁáºÁ GOT7 ÍÂÒ¡·ÑÇÃì¤Í¹àÊÔÃìµÃÍºâÅ¡ à¼ÂÊÔè§·ÕèàÃÕÂ¹ÃÙé¨Ò¡ÈÔÅ»Ô¹ K-POP (¤ÅÔ»)(26 ¾.¤. 2565, 09:00)

á¤»«ÙÅâ´ÂÊÒÃ "ÊµÒÃìäÅà¹ÍÃì" ¢Í§º.âºÍÔé§ ÊËÃÑ°Ï ·´ÊÍº¡ÒÃàª×èÍÁµèÍÊ¶Ò¹ÕÍÇ¡ÒÈ(26 ¾.¤. 2565, 08:50)

ä¿à«ÍÃìà»Ô´â¤Ã§¡ÒÃ ¨Ñ´ÂÒÇÑ¤«Õ¹äÁèáÊÇ§ËÒ¡ÓäÃ(26 ¾.¤. 2565, 08:50)

»Õ·Í§¢Í§ "à´ÕèÂÇ ÊØÃÔÂ¹µì" §Ò¹ÃØÁµèÍà¹×èÍ§ ¤ÃÍ§¨Í 5 ÇÑ¹ ÅÐ¤ÃÍÍ¹áÍÃì¾ÃéÍÁ¡Ñ¹(26 ¾.¤. 2565, 08:48)

ÃÒ¤Ò¹éÓÁÑ¹ÇÑ¹¹Õé 26 ¾ÄÉÀÒ¤Á 2565 àªç¡ÃÒ¤Ò¹éÓÁÑ¹·Ø¡ª¹Ô´ ÅèÒÊØ´ÅÔµÃÅÐ¡ÕèºÒ·(26 ¾.¤. 2565, 08:45)

ÁÇÂ¶Ù¡¤Ùè â€œ»ÃÐ¨Çºâ€ ¤×Í 1 ã¹ 3 ·ÕÁà¤ÂÅéÁ â€œºØÃÕÃÑÁÂìâ€ ªÔ§ÅÕ¡ ¤Ñ¾ ¡èÍ¹´ÇÅ»ÅÒÂà´×Í¹(26 ¾.¤. 2565, 08:28)

ÃÇºáÅéÇ "2 â¨ëàÅ×Í´ÃéÍ¹" ÂÔ§´ÑºË¹ØèÁªèÒ§«èÍÁ¤Í¹â´ ÍéÒ§©Ø¹¢ÑºÃ¶»Ò´Ë¹éÒ(26 ¾.¤. 2565, 08:27)

ã¨ÁÒáÅéÇ á¢é§ 50 ÅéÒ¹»Í¹´ì ¡ÃÐÊÑ¹ÂéÒÂ«º áÁ¹ÂÙÏ «ÑÁàÁÍÃì¹Õé (¤ÅÔ»)(26 ¾.¤. 2565, 08:26)

¤¹ÊÁËÇÑ§ÁÒá¡éº¹ "¾Ò¾Ò¹" äÁèÅ×Á¨Ø´»ÃÐ·Ñ´¢Í "àÅ¢à´ç´§Ç´¹Õé" ÅØé¹âª¤ 1/6/65(26 ¾.¤. 2565, 08:25)

"à·´ÃÍÊ Í´Ò¹ÍÁà¡àºÃàÂ«ØÊ" ¹Ñè§ ¼Í.WHO µèÍÍÕ¡ÇÒÃÐ(26 ¾.¤. 2565, 08:20)

ªÑªªÒµÔ ÊÓÃÇ¨ÊÇ¹ºÒ§¡Í¡ãËè ¾ÃéÍÁÃÑº¹Ñ¡â·ÉÅÍ¡·èÍ àÅ×Í¡ÃÍ§¼ÙéÇèÒÏ àÍ§(26 ¾.¤. 2565, 08:19)

á¹Ð¹ÓÍÒËÒÃáÅÐàÁ¹Ù·ÕèÍØ´Á´éÇÂÇÔµÒÁÔ¹à¤(26 ¾.¤. 2565, 08:01)

àÇçººÍÃì´ >> ÃÑºÃéÍ§àÃÕÂ¹ >>

One

VIEW : 82

â´Â One

UID : äÁèÁÕ¢éÍÁÙÅ
â¾ÊáÅéÇ : 1
µÍºáÅéÇ :
à¾È :
ÃÐ´Ñº : 1
Exp : 20%
à¢éÒÃÐºº :
ÍÍ¿äÅ¹ì :
IP : 98.159.232.xxx

àÁ×èÍ : ¾Ø¸ ·Õè 8 à´×Í¹ ¸Ñ¹ÇÒ¤Á ¾.È.2564 àÇÅÒ 14:13:24

One early casualty was German company CureVac, whose mRNA vaccine yielded disappointing results in a Phase III trial in June, proving just 47% effective at preventing disease. The news was viewed as a setback as the vaccine – which utilised smaller doses of mRNA – was expected to be cheaper, and last longer in storage than the Pfizer/BioNTech and Moderna equivalents.

ÍèÒ¹µèÍä´é·Õè>>> âÃ§àÃÕÂ¹à·ÈºÒÅÇÑ´ä·ÃÍÒÃÕÃÑ¡Éì(Á³ÕÇÔ·ÂÒ)
ÊÒÃÐ¹èÒÃÙé>>> ÁÐàÃç§ÅÓäÊé

[ ÍéÒ§ÍÔ§ ]

Re ËÑÇ¢éÍ :
ÃÙ»»ÃÐ¡Íº :	¨Ó¡Ñ´¢¹Ò´ 100 kB
ÃÒÂÅÐàÍÕÂ´ :	<div style="background-repeat: no-repeat;background-position: left center; background-color :#F3F3F3;width: 520px;border: 1px dashed #FC8A42;"><blockquote > <b>ÍéÒ§ÍÔ§¡ÃÐ·Ùé (Quote Tpoic ID)</b> <font color='orange'>13417</font> â¾ÊáÅéÇ (By) <u><b>One </b></u> : <br><div> One early casualty was German company CureVac, whose mRNA vaccine yielded disappointing results in a Phase III trial in June, proving just 47% effective at preventing disease. The news was viewed as a setback as the vaccine – which utilised smaller doses of mRNA – was expected to be cheaper, and last longer in storage than the Pfizer/BioNTech and Moderna equivalents.</div> <div> <p style="color: rgb(51, 51, 51); font-family: Georgia, "Times New Roman", "Bitstream Charter", Times, serif; font-size: 16px;"> ÍèÒ¹µèÍä´é·Õè>>> <a data-mce-="" href="https://www.tetsabanwatsai.ac.th/">âÃ§àÃÕÂ¹à·ÈºÒÅÇÑ´ä·ÃÍÒÃÕÃÑ¡Éì(Á³ÕÇÔ·ÂÒ)</a><br /> ÊÒÃÐ¹èÒÃÙé>>> <a data-mce-="" href="https://www.tetsabanwatsai.ac.th/%e0%b8%a1%e0%b8%b0%e0%b9%80%e0%b8%a3%e0%b9%87%e0%b8%87%e0%b8%a5%e0%b8%b3%e0%b9%84%e0%b8%aa%e0%b9%89/">ÁÐàÃç§ÅÓäÊé</a></p> <div> </div> </div> <br /> </blockquote><br></div>
	ãÊèÃËÑÊ·Õè·èÒ¹àËç¹Å§ã¹ªèÍ§¹Õé
ª×èÍ¢Í§·èÒ¹ :

Contact

Social Network

WebMaster